Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Intelligent Bio Solutions ( (INBS) ) has provided an announcement.
Intelligent Bio Solutions Inc. has released the initial results of its Pharmacokinetic study necessary for an FDA 510(k) submission, which can now be viewed on their website. The company successfully raised approximately $250,802 through a strategic sale of common stock, capitalizing on their At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc., showcasing their financial growth and investment potential.
For detailed information about INBS stock, go to TipRanks’ Stock Analysis page.
